Generated by AI
Nkarta, Inc. is a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf natural killer (NK) cell therapies. The company’s work centers on engineered cell therapies designed to target autoimmune diseases and, in some programs, hematologic cancers. Nkarta’s pipeline includes product candidates built to improve NK-cell recognition, persistence, and activity through proprietary cell engineering and expansion technologies. Its lead programs are being developed for autoimmune conditions such as lupus nephritis, systemic sclerosis, myasthenia gravis, and ANCA-associated vasculitis, reflecting a broader effort to address diseases driven by abnormal immune activity. Based in South San Francisco, California, Nkarta operates as a biotechnology company within the healthcare sector and is dedicated to advancing scalable, ready-to-use cell therapy platforms for clinical use.
Website1150 Veterans Boulevard
South San Francisco, CA, 94080
United States
The latest articles about NKTX.
Summary of Nov 9's posts. Generated by AI.
Summary of Nov 9's posts. Generated by AI.
Summary of Mar 27's posts. Generated by AI.
Summary of Nov 9's posts. Generated by AI.
Investors talking about NKTX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.